Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Creative photo collage or modern art collage featuring symbols of law and justice. Hand holding a gavel and scales of justice with books about law.

Legal

Judge Rules Against Semaglutide Compounders After Shortage Declared Over

Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run pharmacies must immediately stop making copies of the blockbuster drug.

April 25, 2025

2 min read

Tristan Manalac

Earnings

Gilead’s PrEP Launch Full Speed Ahead Despite Macro Pressures on HIV Space

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch remain on track.

April 25, 2025

3 min read

Tristan Manalac

View of Chicago Skyline from North Avenue Beach

Cancer

Merck, Boehringer Ingelheim, More To Present Key Data at AACR ’25

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment landscape for head and neck and lung cancer, and implications for specific drug modalities like TIGIT and VEGF.

April 25, 2025

4 min read

Tristan Manalac

White arrow on circle wooden move on different direction with black arrow on cube for business and technology disruption concept.

Earnings

BMS Reports Mixed Earnings as Growth Portfolio Makes Up for Generic Pressure

Despite a dip in sales and a recent schizophrenia stumble, the company drew an optimistic outlook for sales for the rest of the year, even as the specter of pharmaceutical tariffs looms.

April 24, 2025

2 min read

Dan Samorodnitsky

Choosing the right path. Business concept. stock photo

Earnings

Tariff Uncertainty Reigns Over Q1 Earnings, With Merck Taking $200M Blow So Far

Merck, Bristol Myers Squibb, Sanofi and Roche had little clarity on the potential impact of President Donald Trump’s pharmaceutical tariffs but many companies are already preparing for what’s to come.

April 24, 2025

3 min read

Annalee Armstrong

Fashionable halftones collage. Startup business concept,fast business startup. Trendy modern retro illustration in bright trendy colors. Strategic planning concept and business success. Vector illustration

Startups

Novartis-, Sanofi-Backed Granite Brings $100M to Compete in Crowded I&I Space

Granite will focus on two antibody therapies, both targeting crucial players in the inflammatory cascade to address autoimmune diseases.

April 24, 2025

2 min read

Tristan Manalac

IN PARTNERSHIP WITH DIA

Economic Challenges, Strategic Investments: Reshaping the Women’s Health Landscape

In this episode presented by DIA, BioSpace’s head of insights Lori Ellis discusses how collaboration and investment shape the the future of women’s health with Martin Hodosi, partner at Kearney and Melissa Laitner, director of strategic initiatives at the National Academy of Medicine.

April 24, 2025

1 min read

Lori Ellis